ESMO Declaration of Interests (DOI) Statement
|
|
- April Payne
- 5 years ago
- Views:
Transcription
1 ESMO Declaration of Interests (DOI) Statement Purpose and disclaimer As leaders in the field of oncology we all have a responsibility to ensure that our work is presented in the most appropriate fashion to protect the integrity of our research and to provide complete transparency. ESMO requires that all Chairs and Speakers participating in ESMO events complete a declaration of interest (DOI) form. Interests that you should disclose are anything which may be perceived as being a conflict between your private interests and your official responsibilities as a person in a position of trust. The declaration of interest must specify all financial interests you have in relation to the following organisations and cover up to the last 5 years: Pharmaceutical, diagnostic, biotechnology, medical technology and research companies, private healthcare providers and commercial medical education providers. You should provide details about any financial interests you may have in the abovementioned organisations, including, but not limited to, employment, honoraria for speaker engagements and advisory roles, funding and ownership of any stocks and shares. In addition, you should also declare non-financial interests which you have directly benefited from and which may be perceived as having enhanced your career, education or professional reputation, and may have given you access to privileged information. ESMO shall neither be responsible for the accuracy, completeness, usability or security of your declaration of interests data, nor shall ESMO be liable for any damage or loss of any sort arising from or relating to any inaccuracy or incompleteness of your declaration, or resulting from any unauthorised access, use or alteration of your data. ESMO s Declaration of Interest Policy can be found on the link below:
2 Personal financial interests 1) Honoraria you have directly received for any speaker, consultancy or advisory role or similar activity e.g. public speaking, writing engagements, expert testimony, participation in a speaker s bureau, which have been paid directly to you by any for-profit health care company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers). Company Comment
3 2) Leadership role in any for-profit healthcare company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers) for which you are financially compensated e.g. as an employee, officer or member of the Board of Directors. Company Comment
4 3) Details of any stocks or ownership interest that you have in any for-profit healthcare company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers). Company Comment
5 4) Licensing fees or royalties that you directly receive from any Intellectual Property (IP) interests relating to the health or medicine industry. Company Comment
6 5) Direct research funding paid directly to you as a project lead (e.g. Principal Investigator) by any for-profit healthcare company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers). Company Comment
7 Institutional financial interests 6) Details of any financial support which has been paid directly to your institution by any for-profit healthcare company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers) in connection with work that you conduct for clinical trials or contracted research. Company Comment
8 Non-financial interests 7) Details of any non-remunerated activities you have performed for any for-profit healthcare company (incl. pharmaceutical, diagnostics, biotechnology, medical technology and research companies or private healthcare or commercial medical education providers) e.g. leadership position, advisory role, principal investigator function or project lead. Details
9 8) Leadership roles you hold in any other medical society, research group, foundation etc. and for which you are not remunerated. Details
10 9) Details of any non-remunerated membership or affiliation with political pressure groups or associations active in the field of oncology. Details
11 Other 10) We encourage you to declare any other relationship, role or activity not captured above, that you currently have or have had in the last 5 years, that you feel may have in some way influenced your work or your professional behaviour. Details
12 No disclosures to make I confirm that none of the above applies to me and that I have no interests to declare. Declaration I hereby declare that the information I have disclosed is true and complete to the best of my knowledge. By completing this form, I consent to disclosing my declaration of interests to meeting participants and confirm that I have included a slide within my presentation with my declaration. Name: Date:
research must complete, even if they have used the coi.asco.org system)
JCO Precision Oncology Author Submission Preparation Worksheet FOR REFERENCE ONLY DO NOT SEND TO JCO PO This worksheet contains: 1. Author Disclosure Form (Authors who do not use the coi.asco.org system
More informationJournal of Clinical Oncology Author Submission preparation worksheet. Author Disclosure Declaration
Journal of Clinical Oncology Author Submission preparation worksheet Each author should complete and return this form to the corresponding author. FOR REFERENCE ONLY DO NOT SEND TO JCO Author Disclosure
More informationFINANCIAL CONFLICT OF INTEREST POLICY
FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary
More informationVersus Arthritis Management of interests policy
Page 1 of 5 Versus Arthritis Management of interests policy Purpose The purpose of this document is to minimise the potential for conflicts of interest to arise and to protect Versus Arthritis and those
More informationAll UCSD Health Faculty (Schools of Medicine and Pharmacy) in the Health Sciences Compensation Plan
TO: All UCSD Health Faculty (Schools of Medicine and Pharmacy) in the Health Sciences Compensation Plan FROM: Andrew Ries, M.D., MPH Associate Vice Chancellor, Academic Affairs UC San Diego Health Sciences
More informationColumbia University MORNINGSIDE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT
Columbia University MORNINGSIDE ANNUAL CONFLICT OF INTEREST DISCLOSURE STATEMENT This information applies to current activities and any activities anticipated during the next 12 months. NOTE: All underlined
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Bulgaria EOOD Registration number 201340239 36 Dragan Tsankov, Bulgaria, Sofia1057 Contents
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca SA 000638901000 4 Theotokopoulou & Astronafton 151 15 Maroussi, Athens, Greece PV: 2290014.1
More informationINSTRUCTIONS AND DEFINITIONS
REPORT OF CATEGORY I, II AND III COMPENSATED OUTSIDE PROFESSIONAL ACTIVITIES, ADDITIONAL TEACHING ACTIVITIES AND INVESTMENT INTERESTS IN HEALTH INDUSTRY COMPANIES FOR THE CALENDAR YEAR 2013 INSTRUCTIONS
More informationDISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST Approved: Board of Directors 06/18/88 Revised: Board of Directors 02/27/98 Revised: Board of Directors 03/19/99 Revised: Board of Directors 05/20/06 Revised:
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 ASTRAZENECA LUXEMBOURG SA N 2002 2220 862 AM BRILL 7B LU-3961 EHLANGE LUXEMBOURG Contents 1. Introduction...
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Eesti OÜ Reg. kood 11733875 Järvevana tee 9 11314 Tallinn Estonia Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction...
More informationAstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach to disclosure
More informationCONFLICTS OF INTEREST IN RESEARCH
IM&COI POLICY III CONFLICTS OF INTEREST IN RESEARCH (Capitalized terms are defined in the Glossary.) Presumption Against Participating in Research When Personal Financial Interests Exist If an Investigator
More informationPaul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support
Administrative Policies and Procedures Manual VMC # 154.02 October 5, 2013 TO: FROM: SUBJECT: REFERENCES: SCVMC Employees Paul Lorenz, MBA Chief Executive Officer, SCVMC Continuing Medical Education (CME)
More informationCreation Date: 7/1/01 Title: Conflict of Interest Revision History:
RENOWN HEALTH Policies & Procedures Page 1 of 6 Current Version Effective Date: 8/16/17 Creation Date: 7/1/01 Title: Conflict of Interest Revision History: Type: Number: Author(s): Owner: Compliance RENOWN.CCD.500
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca UK Limited Registered in England No 3674842 Registered Office, 2 Kingdom Street, London,
More informationAstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016
AstraZeneca AB 556011-7482 151 85 Södertälje Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016 Contents 1. Introduction... 4 Approach to disclosure
More informationFinancial Conflict of Interest. V001 November 14, 2014
Financial Conflict of Interest November 14, 2014 Table of Contents 1 Policy Description... 3 2 Introduction and Scope... 3 3 Definitions... 3 3.1 Terms... 3 3.2 Acronyms... 4 4 Procedure... 5 4.1 Part
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharmaceuticals (Ireland) DAC, Company registration number: 55502 Ireland, Address of
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 LLC «AstraZeneca Ukraine» Legal address: Kyiv, Hvoiky str. 15/15,04080 Ukraine Actual address: Kyiv,
More informationHONORARIA POLICY AND PROCEDURE
HONORARIA POLICY AND PROCEDURE POLICY DESCRIPTION: continuing medical education Policy Governing Honoraria and Reimbursement of Expenses for physicians, and scientists in the role of invited speakers.
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Predstavništvo AstraZeneca UK Limited 29004463 15 Bulevar Vojvode Misica, 11 000 Belgrade, Serbia
More informationAmerican Thoracic Society International Conference SUMMARY AND DEFINITIONS OF ATS POLICIES ON CONFLICT OF INTEREST AND TOBACCO INDUSTRY RELATIONSHIPS
Please note: this document is intended as an optional resource for Conference organizers, chairs and presenters, as a summary of information made available on the ATS COI Website and ATS Website. If you
More informationThe JAMS COI Management Guidance on Eligibility Criteria for Clinical Practice Guideline Formulation March, 2017
The JAMS COI Management Guidance on Eligibility Criteria for Clinical Practice Guideline Formulation March, 07 Table of Contents. Background. Those subject to COI management. Disclosure items and self-disclosure
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...
More informationECHA DECLARATION OF INTERESTS1
Agency. Position in ECHA: Deputy Chair of the Management Board First Name: Henrik Søren Last name: Larsen ECHA Procedure for Prevention and Management of potential Conflicts of Interest. interest. In particular,
More informationCONFLICT OF INTEREST POLICY
Policy Section Name Policy Category Policy Number Supersedes: Corporate Corporate 300CO-CO-005 n/a Organizational Scope IPC (Yes/No) Effective Date Next Review Date ICES-Network (sitespecific procedures)
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
AstraZeneca Latvija 40103252820 Skanstes iela 50, Rīga, LV-1013 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents 1. Introduction... 4 Approach
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
NV ASTRAZENECA SA BE 0400.165.679 110, rue Egide Van Ophemstraat B-1180 Brussels Belgium Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Contents
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationWeill Cornell Medical College Study Specific Form FOR EXTERNAL NON-WCMC USE ONLY. Study Specific Report Form
Weill Cornell Medical College Study Specific Form FOR EXTERNAL NON-WCMC USE ONLY All external users must complete an external SSR whether or not they have any relationships to disclose. * Investigators
More informationNeil Medical Group/Principle LTC Educational Workshop
FULL DISCLOSURE STATEMENT: CONTINUING PROFESSIONAL DEVELOPMENT (CPD) PROGRAM Individuals need to disclose relationships with a commercial interest if both (a) the relationship is financial and occurred
More informationPolicy on Conflicts of Interest in Clinical Care
Policy on Conflicts of Interest in Clinical Care Approved by FPP Board of Directors: March 16, 2006 Revised and Approved: December 15, 2009, January 18, 2011, January 22, 2013, January 21, 2014, April
More informationCONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE
CONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE Background In August 1999, the ACCP Board of Regents approved the policy, Conflict of Interest: ACCP Publications Policy and Procedure. At its
More informationTransfer of Value Disclosure Report as per National Legislation
Merz Pharmaceuticals GmbH Methodological Note Transfer of Value Disclosure Report as per National Legislation 1 I) Introductory note Merz supports laws and obligations which promote transparency around
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationARPIM HCP/HCO DISCLOSURE CODE
ARPIM HCP/HCO DISCLOSURE CODE ARPIM CODE ON THE DISCLOSURE OF SPONSORSHIPS AND OTHER TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
More informationICMJE Form for Disclosure of Potential Conflicts of Interest
Instructions The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More information3. The Executive Committee will determine whether or not a potential donor meets the criteria for acceptance of gifts and grants.
Management of Perceived, Potential or Actual Conflicts of Interest Policy, Procedure and Disclosure Statement National POLST Paradigm Initiative Task Force Approved by Task Force on December 3, 2009 I.
More informationReporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018
Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Österreich GmbH Landstraßer Hauptstraße 1A, 1030 Wien Firmenbuch FN 51184x, HG Wien Contents
More informationCODE OF ETHICS AND PROFESSIONAL STANDARDS FOR MEMBERS
CODE OF ETHICS AND PROFESSIONAL STANDARDS FOR MEMBERS Contents CODE OF ETHICS... 2 1 CONDUCT OF MEMBERS ACTING ON BEHALF OF THE SOCIETY... 2 2 ORGANIZATIONAL POLICIES... 3 3 SPOKESPERSON CONDUCT... 5 4
More informationGilead Transparency Reporting Methodological Note
Gilead Transparency Reporting Methodological Note Contents 1 Introduction... 2 2 Definition of Transfers of Value... 2 3 Definition and management of Cross-Border Spend... 3 4 Which Recipients of Transfers
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationManaging conflicts of interest in the EAU Guidelines GO Policy
Managing conflicts of interest in the EAU Guidelines GO Policy To avoid criticism say nothing, do nothing, be nothing (Aristoteles) Authors: Guidelines Office COI Committee (members): Prof.Dr. A. Bjartell
More informationDisclosure Policy Adopted by NASS Board of Directors: January 13, 2006 Revised October 2008, February 2009, March 2012
Disclosure Policy Adopted by NASS Board of Directors: January 13, 2006 Revised October 2008, February 2009, March 2012 Purpose NASS is a multidisciplinary medical organization dedicated to fostering the
More informationLEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements
LEO Pharma Global Methodological Note to EFPIA HCP/HCO Disclosure Requirements ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP 2/14 Contents 1 Introduction... 3 2 Purpose... 3 3 Terminology and Definitions...
More informationFinancial Disclosure Form for Investigators in PHS Research
Financial Disclosure Form for Investigators in PHS Research Pursuant to Appendix C of The George Washington University Policy on Conflicts of Interest and Commitment for Faculty and Investigators This
More informationLearning Objectives Significant Financial Interest (SFI) Financial Conflict of Interest (FCOI)
Learning Objectives At the end of this training module, you will: Understand the federal COI requirements that guide Northwestern s research COI policies and processes Understand who is subject to research
More informationPharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland
Pharma Cooperation Code Transparency Report 2017 Methodological Note Pfizer Switzerland 1. Table of Content 2. INTRODUCTION... 3 3. PFIZER ACTIVITIES PER EFPIA/SCIENCEINDUSTRIES CATEGORY... 4 4. DEFINITION
More informationCONCISE ANNUAL REPORT 2016 ABN
CONCISE ANNUAL REPORT ABN 24 004 196 909 CONTENTS Chairman s Letter 2 CEO Report 4 Financial Highlights 6 Financial History 7 Directors Report 10 Corporate Governance Statement 46 Concise Financial Report
More informationMethodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Romania Repressentative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
More informationNovartis Methodological Note
Novartis Methodological Note on Disclosure of Payments and other Transfers of Values to Health Care Professionals and Health Care Organizations following the EFPIA Code on Disclosure of Transfers of Value
More informationAASM Conflict of Interest (COI) Policy September 2016
AASM Conflict of Interest (COI) Policy September 2016 Conflict of Interest (COI) Committee Mandate The committee shall consist of no fewer than 3 and no more than 5 members. Each member of the committee
More informationUNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS
UNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS FINANCIAL CONFLICTS OF INTEREST POLICY FOR PUBLIC HEALTH SERVICE (PHS)-FUNDED PROJECTS The University of Wisconsin-Stevens
More informationALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO GROUP
Methodological Note to HCP/HCO Disclosure Requirements in the LEO Group including specifications from LEO Pharma A/S Hungarian Company representative Office ALL LEO TRADEMARKS MENTIONED BELONG TO THE LEO
More informationEuropean Board for Accreditation in Hematology Standards & Guidelines
European Board for Accreditation in Hematology Standards & Guidelines Standards 1 Only CME activities that exclusively benefit hematologists and their patients are eligible for accreditation. 2 Only academic
More informationABPI Disclosure Methodological Note March 2017
ABPI Disclosure Methodological Note March 2017 This note describes the methods used by Roche in the UK to meet its obligations and the requirements for disclosing payments and Transfers of Value (ToV)
More informationAppendix VIII: Conduct of Human Subjects Research in which the University has a significant financial interest Appendix IX: Retrospective
Penn State University College of Medicine (COM) The Penn State Hershey Medical Center (PSHMC) Standard Operating Procedures (SOPs) Regarding Review and Management of Conflict of Interest Version date:
More informationAIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS
AIFP CODE ON DISCLOSURE OF TRANSFERS OF VALUE FROM PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS Approved by the AIFP General Meeting on 21 November 2013, last revision
More informationDISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS
DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS METHODOLOGICAL NOTES Date of Issue: June 2017 Country Scope: Ireland Version: 1.0 CONTENTS INTRODUCTION... 4 CONTENT...
More informationEFPIA Disclosure in Luxembourg Methodology Note - Boehringer Ingelheim
EFPIA Disclosure in Luxembourg Methodology Note - Boehringer Ingelheim 1. Introduction Collaborative working with HealthCare Professionals (HCP) and HealthCare Organizations (HCO) has long been a positive
More informationTitle: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12
Title: Financial Conflicts of Interest Department: Research Institute Effective Date: 3/18 Reviewed: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12 Policy & Procedure Replaces: Disclosure of Conflicts
More informationJanssen disclosure methodology for 2015
Janssen disclosure methodology for 2015 The information below describes the methodology that Janssen has used to disclose the Transfers of Value (ToV) we have made to Healthcare Professionals (HCPs), Other
More informationPolicy, Procedure and Strategies. Conflict of Interest Policy
Policy, Procedure and Strategies Conflict of Interest Policy Issue Document Title Date 1 st Issue Last Reviewed Responsibility of: 01 Conflict of Interest Policy October 2015 Stephen McCartney/ Catherine
More informationDakota State University Policy Manual
Dakota State University Policy Manual SECTION 823 FINANCIAL CONFLICT OF INTEREST PUBLIC HEALTH SERVICE, NATIONAL SCIENCE FOUNDATION OR OTHER APPLICABLE SPONSORED RESEARCH SOURCE: SBHE Policy Manual, Section
More informationCollege of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology. (1) Definitions. The following definitions apply to this regulation:
College of Medicine Policy on Pharmaceutical, Medical Device, and Biotechnology Industry Conflict of Interest (1) Definitions. The following definitions apply to this regulation: (a) COM means the University
More informationDISCLOSURES OF TRANSFERS OF VALUE: SUMMARY OF METHODOLOGY
DISCLOSURES OF TRANSFERS OF VALUE: SUMMARY OF METHODOLOGY 1. ASTELLAS S COMMITMENT 1.1 Astellas is a member company of the European Federation of Pharmaceutical Industries and Associations ( EFPIA ). The
More informationPROCEDURES FOR EVALUATING CONFLICTS OF INTEREST AND COMMITMENT
UNIVERSITY OF COLORADO DENVER PROCEDURES FOR EVALUATING CONFLICTS OF INTEREST AND COMMITMENT [Effective August, 17 2015] Approved by the Conflict of Interest and Commitment Committee on 8-17-15 Approved
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Ireland Year of Disclosure: 2018 for 2017
More informationIPCC CONFLICT OF INTEREST POLICY
IPCC CONFLICT OF INTEREST POLICY Approved at the Thirty-Fourth Session (Kampala, Uganda, 18-19 November 2011) and Annex B amended at the Fortieth Session (Copenhagen, Denmark, 27 31 October 2014) Purpose
More informationSanofi-Aventis Bulgaria EOOD Methodological Note
Sanofi-Aventis Bulgaria EOOD Methodological Note INTRODUCTION Collaboration between healthcare professionals and Pharmaceutical Companies has long been a positive driver for advancements in patient care
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Austria Year of Disclosure: 2018 for 2017
More informationBoehringer Ingelheim Limited Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Registered in England and Wales, No
METHODOLOGICAL NOTE WITH REGARD TO TRANSFERS OF VALUE (ToV) TO HCPs (HEALTHCARE PROFESSIONALS), HCOs (HEALTHCARE ORGANISATIONS) AND ORDMS (OTHER RELEVANT DECISION MAKERS), DURING THE 2016 CALENDAR YEAR:
More informationLETTER OF ENGAGEMENT FOR SERVICES
Chapter Two Australia Pty Ltd Level 57, MLC Centre 19 Martin Place Sydney NSW 2000 GPO Box 348 Sydney NSW 2001 Tel: 02 9238 2285 ABN: 57 607 182 507 LETTER OF ENGAGEMENT FOR SERVICES The purpose of this
More informationPfizer 2016 Disclosure Code Transparency Report
Pfizer 2016 Disclosure Code Transparency Report Methodological Note Pfizer Ireland 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 5 3. SOURCES OF INFORMATION... 7 4. DEFINITION OF THE
More informationMedicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note
Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements Samsung Bioepis Methodology Note 1 Contents 1. Overview of the MFE Requirements 2. Decisions 3. Submission Requirements 4. Categories
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: United Kingdom Year of Disclosure: 2017
More informationMETHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Belgium Year of Disclosure: 2017 for 2016
More informationCAROLINAS HEALTHCARE SYSTEM OFFICE OF CLINICAL AND TRANSLATIONAL RESEARCH STANDARD OPERATING PROCEDURE
CAROLINAS HEALTHCARE SYSTEM OFFICE OF CLINICAL AND TRANSLATIONAL RESEARCH STANDARD OPERATING PROCEDURE Procedure No.: A-106 Title: Disclosure and Management of Significant Financial Interest in CHS Research
More informationMONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE
MONTEFIORE HEALTH SYSTEM ADMINISTRATIVE POLICY AND PROCEDURE SUBJECT: CONFLICT OF INTEREST NUMBER: JH20.1 OWNER: DEPARTMENT OF COMPLIANCE EFFECTIVE: REVIEW/REVISED: SUPERSEDES: 10/15 10/15 CROSS-REFERENCE:
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Biogen Methodology Note Contents Overview of the EFPIA Requirements... 3 Decisions...
More informationStandard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest
Standard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest Effective May 1, 2013 TABLE OF CONTENTS 1.0 GENERAL PRINCIPLES... 3 2.0 SCOPE... 3 3.0 GUIDING PRINCIPLES...
More informationUniversity of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005
University of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005 Revised August 2012 Table of Contents Introduction... 3 Background...
More informationPolicy Number: Location: Origination Date: Date of Last Review: Baylor Research Institute 8/24/2012 7/11/2012
Policy Name: Financial Conflict of Interest in Research Policy Department/Service Line: Research Subject Protection Policy Number: BHCS.BRI.SP.811.P.V12 Location: Origination Date: Date of Last Review:
More informationEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire Contents 1. Overview of the EFPIA Requirements... 3 2.
More informationDisclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi
Disclosure 2015 Methodological Note For Aventis Pharma Ltd trading as Sanofi INTRODUCTION The EFPIA Disclosure Code requires all EFPIA member companies to disclose transfers of value (TOV) such as support
More informationGraduate Medical Education Medical Industry Interaction Policy and Procedure. December 18, 2008
Graduate Medical Education Medical Industry Interaction Policy and Procedure December 18, 2008 Purpose: To ensure that all residents and fellows interactions with representatives of the pharmaceutical
More informationBioMarin RareConnections Patient Enrollment Form for CLN2 Disease
BioMarin RareConnections Patient Enrollment Form for CLN2 Disease Fax completed form to 1-888-863-3361 or email to support@biomarin-rareconnections.com Phone: 1-866-906-6100 Hours: M F 6 AM 5 PM (PST)
More informationPfizer 2015 Disclosure Code Transparency Report
Pfizer 2015 Disclosure Code Transparency Report Methodological Note Pfizer Ireland 1. INTRODUCTION... 3 2. PFIZER ACTIVITIES PER EFPIA CATEGORY... 4 3. SOURCES OF INFORMATION... 6 4. DEFINITION OF THE
More informationPolicy Name. Effective Date 10/23/2017 Approved Date 10/23/2017 Next Approval Date 10/23/2018 Policy Owner
Approved by: Michael Salem, CEO POLICY STATEMENT Policy Name Institutional Policy Effective Date 10/23/2017 Approved Date 10/23/2017 Next Approval Date 10/23/2018 Policy Owner Conflict of Interest and
More informationBRISTOL-MYERS SQUIBB GLOBAL TERMS AND CONDITIONS FOR HEALTHCARE CONSULTANCY SERVICES (Version dated May 15, 2015)
BRISTOL-MYERS SQUIBB GLOBAL TERMS AND CONDITIONS FOR HEALTHCARE CONSULTANCY SERVICES (Version dated May 15, 2015) 1 DEFINITIONS Affiliate. A legal entity which directly or indirectly Controls, is under
More informationMethodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code
Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code Date Published: 31 May 2017 Index Annex 1: The disclosure in accordance with the Schedule 2 Template Annex
More informationNYU LANGONE POLICY ON CONFLICTS OF INTEREST IN BUSINESS AFFAIRS. Issue Date: April 1, 2009 Reissue Date: June 29, Contents: I.
NYU LANGONE POLICY ON CONFLICTS OF INTEREST IN BUSINESS AFFAIRS Issue Date: April 1, 2009 Reissue Date: June 29, 2016 Contents: I. Applicability II. General Policy III. Procedures for Disclosure IV. Review
More informationFinancial Conflict of Interest
Financial Conflict of Interest In August 2012, the U.S. Public Health Service (PHS) of the U.S. Department of Health and Human Services, which includes NIH, began to enforce new regulations on financial
More informationThis document explains the methodology underlying Roche s EFPIA disclosure
This document explains the methodology underlying Roche s EFPIA disclosure It is common in many innovation-led industries for companies to engage independent experts or specialist organizations. Collaborations
More informationREGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH
REGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH I. INTRODUCTION This Financial Conflicts of Interest Policy for PHS-Funded Research ( FCOI Policy ) implements
More informationIsland Health Guidelines for Commercial Support of Continuing Medical Education/Continuing Professional Development Activities
Continuing Professional Development for Physicians Island Health Guidelines for Commercial Support of The following document outlines the guiding principles pertaining to the support of VIHA sponsored
More information